The emergence of a recent COVID-19 variant, dubbed “Cigarra” (BA.3.2), is prompting increased monitoring from global health experts. This latest iteration of the virus, a descendant of the Omicron strain that fueled a significant surge in infections in late 2021, is notable for its unusually high number of mutations – exceeding 70 – raising concerns about its potential to evade existing immunity. While currently assessed as a low-risk variant, the World Health Organization (WHO) and other public health bodies are closely tracking its spread and characteristics.
Understanding the evolving nature of SARS-CoV-2, the virus that causes COVID-19, remains crucial as we navigate the ongoing pandemic. The virus’s ability to mutate is a fundamental aspect of its behavior, and each new variant presents a unique set of challenges. The “Cigarra” variant, with its substantial genetic changes, is no exception. This new variant is currently circulating in over 20 countries, though its impact hasn’t yet resulted in a massive wave of infections. The primary concern centers on its potential to diminish the effectiveness of both vaccines and prior infection-derived immunity, a phenomenon known as immune evasion.
What Makes ‘Cigarra’ Different?
The Omicron variant, first identified in November 2021, was already characterized by a large number of mutations compared to earlier strains. However, BA.3.2, or “Cigarra,” takes this a step further. According to the WHO, the variant’s extensive mutations warrant close observation, even though it is currently classified as a low-risk variant. The sheer number of changes in its genetic structure could influence how the virus interacts with the human immune system and the effectiveness of current preventative measures.
Kyle B. Enfield, a professor of medicine at the University of Virginia, explained the underlying mechanism driving these changes. “Each time the virus replicates within a cell, its genetic material mutates,” he stated, highlighting that this process gives the virus an evolutionary advantage. This rapid mutation rate can make it more difficult for vaccines to recognize and neutralize the virus, potentially allowing it to spread more easily. The WHO is actively monitoring the development of BA.3.2, providing regular updates on its characteristics and spread through reports like the one published on May 12, 2025, available on their website.
Symptoms and Severity of Infection
Early data suggests that infections with the “Cigarra” variant generally present as mild to moderate, particularly in individuals who have been vaccinated against COVID-19. The reported symptoms are similar to those associated with other COVID-19 variants and common respiratory illnesses, including:
- Fever
- Cough
- Sore throat
- Fatigue
- Muscle aches
- Headache
These symptoms can overlap with those of other respiratory infections, making accurate diagnosis challenging. This overlap underscores the importance of testing to confirm a COVID-19 diagnosis and guide appropriate care. While initial reports indicate lower clinical severity, ongoing surveillance is essential to monitor for any shifts in the disease profile.
Impact of Vaccination and Prior Infection
A key question surrounding the “Cigarra” variant is its ability to evade immunity conferred by vaccination or previous infection. Reports indicate that the variant *could* reduce the protection offered by these factors, though the extent of this reduction is still being investigated. This potential for immune evasion doesn’t negate the benefits of vaccination. rather, it highlights the importance of staying up-to-date with recommended booster doses. Vaccination continues to provide significant protection against severe illness, hospitalization, and death, even against variants with increased immune evasion capabilities.
Mexico has been actively working to bolster its vaccine production capabilities, recently signing agreements with laboratories to produce vaccines against COVID-19, dengue fever, and cancer, as reported on February 9, 2026. This initiative aims to strengthen the country’s preparedness for future outbreaks and ensure access to essential vaccines for its population.
What to Expect Moving Forward
The emergence of the “Cigarra” variant serves as a reminder that the COVID-19 pandemic is not over. Continued genomic surveillance, robust testing programs, and widespread vaccination efforts remain critical to managing the virus and mitigating its impact. Public health officials emphasize the importance of staying informed about the latest developments and following recommended preventative measures, such as practicing good hygiene, wearing masks in crowded indoor settings, and getting vaccinated and boosted when eligible.
The WHO continues to monitor the BA.3.2 variant closely, and will provide updated risk assessments as more data becomes available. The next scheduled update from the WHO regarding variants of interest is expected in late June 2026. Staying vigilant and informed is the best course of action as we continue to navigate the evolving landscape of COVID-19.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What are your thoughts on the new variant? Share your comments below, and please share this article with your network to help spread awareness.
